These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Discovery of G Protein-Biased Dopaminergics with a Pyrazolo[1,5-a]pyridine Substructure. Möller D; Banerjee A; Uzuneser TC; Skultety M; Huth T; Plouffe B; Hübner H; Alzheimer C; Friedland K; Müller CP; Bouvier M; Gmeiner P J Med Chem; 2017 Apr; 60(7):2908-2929. PubMed ID: 28248104 [TBL] [Abstract][Full Text] [Related]
7. D Shen Y; McCorvy JD; Martini ML; Rodriguiz RM; Pogorelov VM; Ward KM; Wetsel WC; Liu J; Roth BL; Jin J J Med Chem; 2019 May; 62(9):4755-4771. PubMed ID: 30964661 [TBL] [Abstract][Full Text] [Related]
8. Protean agonism at the dopamine D2 receptor: (S)-3-(3-hydroxyphenyl)-N-propylpiperidine is an agonist for activation of Go1 but an antagonist/inverse agonist for Gi1,Gi2, and Gi3. Lane JR; Powney B; Wise A; Rees S; Milligan G Mol Pharmacol; 2007 May; 71(5):1349-59. PubMed ID: 17287401 [TBL] [Abstract][Full Text] [Related]
9. G protein coupling and ligand selectivity of the D2L and D3 dopamine receptors. Lane JR; Powney B; Wise A; Rees S; Milligan G J Pharmacol Exp Ther; 2008 Apr; 325(1):319-30. PubMed ID: 18218829 [TBL] [Abstract][Full Text] [Related]
10. Functional potencies of dopamine agonists and antagonists at human dopamine D₂ and D₃ receptors. Tadori Y; Forbes RA; McQuade RD; Kikuchi T Eur J Pharmacol; 2011 Sep; 666(1-3):43-52. PubMed ID: 21658377 [TBL] [Abstract][Full Text] [Related]
11. S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: I. Receptor-binding profile and functional actions at G-protein-coupled receptors. Millan MJ; Mannoury la Cour C; Novi F; Maggio R; Audinot V; Newman-Tancredi A; Cussac D; Pasteau V; Boutin JA; Dubuffet T; Lavielle G J Pharmacol Exp Ther; 2008 Feb; 324(2):587-99. PubMed ID: 18024789 [TBL] [Abstract][Full Text] [Related]
12. In vitro pharmacology of aripiprazole, its metabolite and experimental dopamine partial agonists at human dopamine D2 and D3 receptors. Tadori Y; Forbes RA; McQuade RD; Kikuchi T Eur J Pharmacol; 2011 Oct; 668(3):355-65. PubMed ID: 21816144 [TBL] [Abstract][Full Text] [Related]
13. Bivalent dopamine D2 receptor ligands: synthesis and binding properties. Kühhorn J; Hübner H; Gmeiner P J Med Chem; 2011 Jul; 54(13):4896-903. PubMed ID: 21599022 [TBL] [Abstract][Full Text] [Related]
14. 1,4-Disubstituted aromatic piperazines with high 5-HT2A/D2 selectivity: Quantitative structure-selectivity investigations, docking, synthesis and biological evaluation. Möller D; Salama I; Kling RC; Hübner H; Gmeiner P Bioorg Med Chem; 2015 Sep; 23(18):6195-209. PubMed ID: 26299826 [TBL] [Abstract][Full Text] [Related]
15. Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor. Grundt P; Carlson EE; Cao J; Bennett CJ; McElveen E; Taylor M; Luedtke RR; Newman AH J Med Chem; 2005 Feb; 48(3):839-48. PubMed ID: 15689168 [TBL] [Abstract][Full Text] [Related]
16. Novel roles for β-arrestins in the regulation of pharmacological sequestration to predict agonist-induced desensitization of dopamine D3 receptors. Min C; Zheng M; Zhang X; Caron MG; Kim KM Br J Pharmacol; 2013 Nov; 170(5):1112-29. PubMed ID: 23992580 [TBL] [Abstract][Full Text] [Related]
17. In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist. Glennon JC; Van Scharrenburg G; Ronken E; Hesselink MB; Reinders JH; Van Der Neut M; Long SK; Feenstra RW; McCreary AC Synapse; 2006 Dec; 60(8):599-608. PubMed ID: 17001660 [TBL] [Abstract][Full Text] [Related]
18. New pyridobenzoxazepine derivatives derived from 5-(4-methylpiperazin-1-yl)-8-chloro-pyrido[2,3-b][1,5]benzoxazepine (JL13): chemical synthesis and pharmacological evaluation. Liégeois JF; Deville M; Dilly S; Lamy C; Mangin F; Résimont M; Tarazi FI J Med Chem; 2012 Feb; 55(4):1572-82. PubMed ID: 22268448 [TBL] [Abstract][Full Text] [Related]
19. Synthesis and evaluation in rats of the dopamine D2/3 receptor agonist 18F-AMC20 as a potential radioligand for PET. Shalgunov V; van Wieringen JP; Janssen HM; Fransen PM; Dierckx RA; Michel MC; Booij J; Elsinga PH J Nucl Med; 2015 Jan; 56(1):133-9. PubMed ID: 25476538 [TBL] [Abstract][Full Text] [Related]
20. Modification of agonist binding moiety in hybrid derivative 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-1-ol/-2-amino versions: impact on functional activity and selectivity for dopamine D2/D3 receptors. Gopishetty B; Zhang S; Kharkar PS; Antonio T; Reith M; Dutta AK Bioorg Med Chem; 2013 Jun; 21(11):3164-74. PubMed ID: 23623679 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]